[ad_1]
In the UK, more than half a million children missed a first dose of measles vaccine between 2010 and 2017, according to figures released by UNICEF last week.
Simon Stevens, managing director of NHS England, warned that public rejection of the vaccine was "a serious and growing time bomb for public health".
According to UNICEF estimates, 169 million children worldwide have not received the first dose of measles vaccine in the world.
Executive Director Henrietta Fore said: "The outbreak of measles outbreaks that we have seen today was years ago, and the measles virus will still find unvaccinated children. really prevent the spread of this dangerous but preventable disease, we must vaccinate all children, both in rich countries and in poor countries. "
In the first three months of 2019, more than 110,000 cases of measles were reported worldwide, an increase of almost 300% over the same period last year. Figures show that about 110,000 people, most of them children, died of measles in 2017, an increase of 22% over the previous year.
The United States tops the list of high-income countries with the largest number of children having not received the first dose of the vaccine between 2010 and 2017, according to UNICEF. The United Kingdom was in third place, behind France, with 527,000 children who had not received their first dose of measles vaccine during the same period.
Mary Ramsay, Vaccinations Officer at Public Health England, said: "These numbers highlight the importance not only of routine immunization, but also of the fact that anyone who forgets a dose is caught up in order to minimize the risk. risk of epidemic. "
NHS England said it is concerned that many parents have been sent back to vaccinate their children because of an unfounded opposition to vaccination. "Measles cases almost quadrupled in England in just one year, it is absolutely irresponsible to spread alarmist information about vaccines, and social media companies should adopt a zero-tolerance policy with respect to this content. dangerous, "said Stevens on Wednesday.
End of life care
Among this week's announcements from the National Institute for Excellence in Health and Care (NICE) was a draft directive regarding the organization and provision of adult care by the end of the year. life.
The care of a patient should be regularly reviewed by a senior health professional (the recommendation is recommended), while good communication should be maintained between the patient, the caregiver and the practitioner to ensure a common understanding of needs.
A caregiver needs badessment was one of the new recommendations. The guideline indicated that it was important to take into account the age of caregivers, as the needs of younger and older caregivers might differ.
Evidence has shown that, if supported, caregivers could help maintain a better quality of life for the dying person according to the directive. Practitioners should therefore be encouraged to listen to caregivers' needs, to take into account the physical and emotional strains they may experience, and to see how their needs can be met as well as those of their loved ones.
The draft directive, intended to be used alongside NICE's directive on the care of dying adults in the last days of life, was submitted for consultation until 7th June, the final publication is scheduled for October 2019.
Treatment of T-cell lymphoma
Brentuximab vedotin (Adcetris, Takeda) has been recommended as a treatment option for CD30-positive T-cell cutaneous lymphoma (CTCL) in adults after at least one systemic treatment.
NICE stated that clinical trial evidence suggested that the antibody-drug conjugate was more effective than methotrexate or bexarotene (Targretin, Eisai) in terms of response rate and life expectancy without aggravation of the disease.
In the latest guidelines, patients would be eligible if they had stage IIB fungoid mycosis or more, primary cutaneous anaplastic lymphoma, or Sezary syndrome.
The recommendation depended on the manufacturer supplying the brentuximab vedotin at an agreed price.
Help prevent suicides
A consultation was launched on a draft quality standard for suicide prevention.
NICE has stated that it sets out ways to reduce the number of suicides and to help people who are grieving or affected by suicide, whether in the community or in detention.
Interested parties have until 23rd May to comment before a final document expected in September 2019.
Rectal cancer treatment "lack of evidence"
An evaluation of low energy X-ray contact brachytherapy (Papillon technique) for locally advanced rectal cancer revealed that current safety and efficacy data were insufficient in quantity and quality.
NICE has initiated a consultation on its guidance project which recommends that the procedure be used for research purposes only.
In the draft guidance, he advocated additional research to include randomized controlled trials comparing the procedure to standard care.
The consultation will end on 23rd May, and final guidelines are expected by August 2019.
NICE "not willing" to recommend treatment of type 1 diabetes
An evaluation consultation was announced after NICE stated that it did not intend to recommend dapagliflozin (ForxigaAstraZeneca) with insulin as a treatment option for type 1 diabetes in adults with a BMI of at least 27 kg / m2, while insulin alone does not provide adequate glycemic control despite optimal insulin therapy.
In an orientation project, an evaluation committee stated that the clinical evidence suggested that, compared to placebo, there were slight improvements in blood glucose (hbA1c levels) and weight loss, as well as very slight improvements in quality of life through treatment. However, there is no clinical evidence indicating the duration of life of patients after dapagliflozin treatment.
The consultation will last until 17th May 2019.
Treatment of type 2 diabetes
In the draft guideline, NICE recommended ertugliflozin (Steglatro, Merck Sharp & Dohme) with metformin and a dipeptidyl peptidase-4 (DPP-4) inhibitor as an option for the treatment of type 2 diabetes in adults when diet and exercise do not allow adequate glycemic control.
Patients would be eligible only if the disease was uncontrolled by metformin and a DPP-4 inhibitor, as well as a sulfonylurea or pioglitazone (Actos, Takeda and others) was not appropriate.
Treat hyperkalemia
Cyclosilicate of sodium and zirconium (LokelmaAstraZeneca) has been recommended as an option for the treatment of hyperkalemia in adults, NICE said in a draft guideline.
Patients would only be eligible if treatment was needed in an emergency care setting and that the drug was stopped after 28 days of maintenance treatment or earlier if hyperkalemia disappeared.
However, zirconium and sodium cyclosilicate was not recommended for ambulatory patients because it was considered too expensive.
A consultation on the draft directive ends on 20th May 2019.
Bioprosthetic card for bad fistula
Current evidence on the safety and effectiveness of inserting a bioprosthetic plug for bad fistula was sufficient to support the use of the procedure, NICE said in a statement. draft directive.
Treatment could be provided provided that standard provisions are in place for clinical governance, consent and audit – and when they are undertaken by a surgeon experienced in the management of bad fistulas.
A consultation on the guidelines will end on 23rd May, the latest directives being planned for September 2019.
Intracranial aneurysm procedure
NICE announced that it was consulting on a draft directive on the endovascular insertion of a device for disruption of intracascular wire mesh blood flow for intracranial aneurysm.
He indicated that current evidence on the safety and effectiveness of the procedure was sufficient to justify its use, provided that standard provisions are in place for clinical governance, consent and audit.
The consultation period will last until 23rd May, the last orientations being planned for August 2019.
[ad_2]
Source link
